Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) kicked off on Tuesday, down -2.28% from the previous trading day, before settling in for the closing price of $762.00. Over the past 52 weeks, REGN has traded in a range of $750.20-$1211.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 19.99% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 2.40%. With a float of $105.94 million, this company’s outstanding shares have now reached $107.60 million.
In an organization with 13450 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 83.54%, operating margin of 28.92%, and the pretax margin is 35.89%.
Regeneron Pharmaceuticals, Inc (REGN) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Regeneron Pharmaceuticals, Inc is 3.59%, while institutional ownership is 86.03%. The most recent insider transaction that took place on Nov 01 ’24, was worth 844,610. In this transaction EVP Commercial of this company sold 1,000 shares at a rate of $844.61, taking the stock ownership to the 12,931 shares. Before that another transaction happened on Nov 01 ’24, when Company’s Officer proposed sale 1,000 for $844.61, making the entire transaction worth $844,610.
Regeneron Pharmaceuticals, Inc (REGN) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported 11.86 earnings per share (EPS), higher than consensus estimate (set at 10.75) by 1.11. Wall Street market experts anticipate that the next fiscal year will bring earnings of 10.99 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.40% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 5.51% during the next five years compared to 10.31% growth over the previous five years of trading.
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) Trading Performance Indicators
Take a look at Regeneron Pharmaceuticals, Inc’s (REGN) current performance indicators. Last quarter, stock had a quick ratio of 4.46. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.91. Likewise, its price to free cash flow for the trailing twelve months is 23.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 40.41, a number that is poised to hit 11.09 in the next quarter and is forecasted to reach 45.04 in one year’s time.
Technical Analysis of Regeneron Pharmaceuticals, Inc (REGN)
Let’s dig in a bit further. During the last 5-days, its volume was 1.01 million. That was better than the volume of 0.53 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 8.17%. Additionally, its Average True Range was 23.21.
During the past 100 days, Regeneron Pharmaceuticals, Inc’s (REGN) raw stochastic average was set at 1.77%, which indicates a significant decrease from 5.72% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 40.37% in the past 14 days, which was higher than the 26.82% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $969.72, while its 200-day Moving Average is $1,004.59. However, in the short run, Regeneron Pharmaceuticals, Inc’s stock first resistance to watch stands at $756.74. Second resistance stands at $768.87. The third major resistance level sits at $779.15. If the price goes on to break the first support level at $734.33, it is likely to go to the next support level at $724.05. Assuming the price breaks the second support level, the third support level stands at $711.92.
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) Key Stats
The company with the Market Capitalisation of 81.82 billion has total of 109,890K Shares Outstanding. Its annual sales at the moment are 13,117 M in contrast with the sum of 3,954 M annual income. Company’s last quarter sales were recorded 3,721 M and last quarter income was 1,341 M.
